A phase 1 trial of GenSci120 for the treatment of Rheumatoid Arthritis
Latest Information Update: 25 Feb 2025
At a glance
- Drugs GenSci 120 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
Most Recent Events
- 25 Feb 2025 New trial record
- 17 Jan 2025 According to a Changchun GeneScience Pharmaceutical Co., Ltd. media release, company announced that the National Medical Products Administration (NMPA) has approved an IND application for the PD-1 agonist GenSci120 for the treatment of Rheumatoid Arthritis.